Lytix Biopharma AS (OSL: LYTIX)
Norway
· Delayed Price · Currency is NOK 5.74
-0.02 (-0.35%)
Jan 17, 2025, 4:03 PM CET
Lytix Biopharma AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 10.76 | 3.99 | 11.03 | 19.31 | 0 | 0.31 | Upgrade
|
| Other Revenue | - | - | - | - | 4.07 | 6.03 | Upgrade
|
| Revenue | 10.76 | 3.99 | 11.03 | 19.31 | 4.07 | 6.34 | Upgrade
|
| Revenue Growth (YoY) | -20.98% | -63.82% | -42.87% | 373.91% | -35.73% | -46.38% | Upgrade
|
| Gross Profit | 10.76 | 3.99 | 11.03 | 19.31 | 4.07 | 6.34 | Upgrade
|
| Selling, General & Admin | 20.85 | 24.37 | 20.41 | 31.1 | 24.81 | 22.83 | Upgrade
|
| Research & Development | 60.31 | 63.17 | 45.61 | 23.74 | 16.01 | 14.02 | Upgrade
|
| Other Operating Expenses | 11.51 | 12.28 | 9.76 | 12.01 | 5.63 | 3.26 | Upgrade
|
| Operating Expenses | 93.61 | 100.78 | 76.7 | 67.29 | 46.45 | 40.11 | Upgrade
|
| Operating Income | -82.86 | -96.79 | -65.67 | -47.99 | -42.37 | -33.77 | Upgrade
|
| Interest Expense | -4.66 | -0.06 | -0.15 | -0.07 | - | - | Upgrade
|
| Interest & Investment Income | - | 2.35 | 1.41 | 0.14 | 0.35 | 0.46 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.01 | 4.01 | 7.72 | -0.17 | -0.07 | -0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.58 | 2.59 | 0.61 | 0.01 | 0.01 | 0.34 | Upgrade
|
| EBT Excluding Unusual Items | -80.92 | -87.9 | -56.07 | -48.08 | -42.09 | -33.23 | Upgrade
|
| Pretax Income | -80.92 | -87.9 | -56.07 | -48.08 | -42.09 | -33.23 | Upgrade
|
| Earnings From Continuing Operations | -80.92 | -87.9 | -56.07 | -48.08 | -42.09 | -33.23 | Upgrade
|
| Net Income | -80.92 | -87.9 | -56.07 | -48.08 | -42.09 | -33.23 | Upgrade
|
| Net Income to Common | -80.92 | -87.9 | -56.07 | -48.08 | -42.09 | -33.23 | Upgrade
|
| Shares Outstanding (Basic) | - | 40 | 40 | 33 | 26 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | - | 40 | 40 | 33 | 26 | 23 | Upgrade
|
| Shares Change (YoY) | - | 1.01% | 19.50% | 26.57% | 14.56% | 1.78% | Upgrade
|
| EPS (Basic) | - | -2.19 | -1.41 | -1.45 | -1.60 | -1.45 | Upgrade
|
| EPS (Diluted) | - | -2.19 | -1.41 | -1.45 | -1.60 | -1.45 | Upgrade
|
| Free Cash Flow | -81.91 | -95.75 | -52.78 | -44.61 | -24.35 | -36.82 | Upgrade
|
| Free Cash Flow Per Share | - | -2.39 | -1.33 | -1.34 | -0.93 | -1.61 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -770.24% | -2425.08% | -595.28% | -248.54% | -1040.06% | -532.78% | Upgrade
|
| Profit Margin | -752.26% | -2202.38% | -508.29% | -249.02% | -1033.09% | -524.17% | Upgrade
|
| Free Cash Flow Margin | -761.49% | -2399.02% | -478.47% | -231.04% | -597.62% | -580.85% | Upgrade
|
| EBITDA | -82.79 | -96.72 | -65.64 | -47.53 | - | -33.77 | Upgrade
|
| EBITDA Margin | - | - | - | -246.20% | - | - | Upgrade
|
| D&A For EBITDA | 0.07 | 0.06 | 0.03 | 0.45 | - | 0.01 | Upgrade
|
| EBIT | -82.86 | -96.79 | -65.67 | -47.99 | -42.37 | -33.77 | Upgrade
|
| EBIT Margin | - | - | - | -248.54% | - | - | Upgrade
|
| Revenue as Reported | 10.76 | 3.99 | 11.03 | 19.5 | 6.68 | 6.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.